Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiasthma Drugs: Methylxanthines

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...

Adrenergic Agonists: Mixed-Action Agents

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...

Antiasthma Drugs: Muscarinic Receptor Antagonists

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Adrenergic Agonists: Direct-Acting Agents

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ILCOR Pediatric Life Support 2025: What is New and Why it Matters?

Indian journal of pediatrics·2026

Same author

Effect of remote ischemic conditioning on albuminuria in adults with diabetes mellitus (ricadime): a parallel group, double blind, sham controlled, randomized clinical trial.

Postgraduate medical journal·2026

Same author

Validation of a Clinical Tool to Predict Neurological Outcomes in Critically Ill Children-A Prospective Observational Study: Authors' Reply.

Indian journal of pediatrics·2026

Same author

Perioperative management consideration for congenital syngnathia: a multidisciplinary approach.

BMJ case reports·2026

Same author

ContraIndicator: A Natural Language Processing-Based Approach to Potential Drug-Drug Interaction Detection in Pediatric Intensive Care.

Clinical drug investigation·2026

Same author

Immune Dysregulation in Pediatric Sepsis and the Way Towards Precision Guided Therapy.

Indian journal of pediatrics·2026

Search research articles

Related Experiment Video

Updated: Jul 6, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Doxofylline: The next generation methylxanthine.

Jhuma Sankar¹, Rakesh Lodha, S K Kabra

¹Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.

Indian Journal of Pediatrics

|April 1, 2008

Summary

This summary is machine-generated.

Doxofylline, a new methylxanthine, shows promise for treating asthma in children, offering similar efficacy to theophylline with fewer side effects. This oral medication may be a valuable option, especially in resource-limited settings.

More Related Videos

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

Related Experiment Videos

Last Updated: Jul 6, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

Area of Science:

Pharmacology
Pediatric Pulmonology

Background:

Methylxanthines, like theophylline, are oral asthma treatments beneficial in resource-limited settings.
Theophylline has a narrow therapeutic index and significant adverse effects, leading to poor patient compliance.
Doxofylline, a novel methylxanthine derivative, demonstrates comparable efficacy and improved safety in adults, but data in children are limited.

Purpose of the Study:

To evaluate the efficacy and safety of doxofylline in pediatric asthma patients.
To compare doxofylline with theophylline as an add-on therapy for asthma in children.
To assess the potential of doxofylline as an alternative oral methylxanthine in pediatric asthma management.

Main Methods:

Retrospective analysis of pediatric asthma patients treated with doxofylline.
Review of available animal and human adult studies on doxofylline's efficacy and safety.
Extrapolation of adult data to inform potential pediatric use and dosing.

Main Results:

Doxofylline demonstrated improvement in spirometric parameters in children with asthma compared to placebo.
Retrospective data indicated a low incidence of side effects (11% overall, 5% moderate).
Doxofylline produces stable serum concentrations, reducing the need for routine monitoring.

Conclusions:

Doxofylline shows potential as an effective and safer alternative to theophylline for pediatric asthma.
It may be considered as add-on therapy in Step 3 and Step 4 asthma management for children over 6 years.
Routine plasma monitoring for doxofylline is generally not required, except in specific patient groups.